Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2021
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.
October 2021
A Randomized, Controlled Double-Blind Study Comparing The Efficacy And Safety Of Dose-Ranging Voclosporin With Placebo In Achieving Remission In Patients With Active Lupus Nephritis
Kidney Int 2019;95:219–31
Calcineurin inhibitors have the potential to increase the likelihood of complete renal remission (CRR) when added to standard-of-care induction therapy for LN.
Baricitinib for Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 2018;392:222–31
This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.
Keywords:
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Arthritis Rheumatol 2017;69:376–86
One of the challenges of treating SLE is the limited efficacy and poor tolerability of current therapies.